CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 1.96×, higher than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score -0.65: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
298.08MEUR348.02M · vs all stocks (USD)
Revenue (TTM)
55.10MUSD64.33M · vs all stocks (USD)
Profit Margin
-102.34%vs Biotechnology peers
Beta
2.75xvs all stocks
52-Week Change
17.21%vs all stocks
Market Capitalization
298.08MEUR348.02M · vs all stocks (USD)
Enterprise Value
91.78MEUR107.16M · vs all stocks (USD)
Forward P/E
-1.73xvs Biotechnology peers
Price to Sales (TTM)
4.32xvs Biotechnology peers
Price to Book (MRQ)
5.62xvs Biotechnology peers
Enterprise to Revenue
1.67xvs Biotechnology peers
Enterprise to EBITDA
-2.28xvs Biotechnology peers
Gross Margin
54.96%vs Biotechnology peers
Profit Margin
-102.34%vs Biotechnology peers
Operating Margin
-340.69%vs Biotechnology peers
Return on Assets (TTM)
-11.67%vs Biotechnology peers
Return on Equity (TTM)
-94.54%vs Biotechnology peers
Revenue (TTM)
55.10MUSD64.33M · vs all stocks (USD)
Revenue per Share (TTM)
0.6350USDUpdated Aug 21, 2026Quarterly Revenue Growth
-62.10%vs Biotechnology peers
EBITDA (TTM)
-40.30MUSD-47.05M · vs all stocks (USD)
Net Income (TTM)
-56.39MUSD-65.83M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-68.74%vs Biotechnology peers
Operating Cash Flow (TTM)
-35.94MUSD-41.96M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
72.95MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
9.80MUSDFY2025 · Dec 31, 2025Gross Profit
63.15MUSDFY2025 · Dec 31, 2025Operating Income
-33.08MUSDvs all stocks (USD)
Pre-tax Income
-68.02MUSDFY2025 · Dec 31, 2025Income Tax Expense
-423.00KUSDFY2025 · Dec 31, 2025Net Income
-67.59MUSDFY2025 · Dec 31, 2025EBIT
-59.91MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-3.52MUSDFY2025 · Dec 31, 2025Research & Development
93.52MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
8.60MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-7.28MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.11MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-67.59MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-48.50MUSDFY2025 · Dec 31, 2025Free Cash Flow
-50.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
61.53MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-67.59MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
20.06MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-423.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
34.94MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-9.45MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.26MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-28.88MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.36MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.17MUSDFY2025 · Dec 31, 2025Purchase of Investments
-159.78MUSDFY2025 · Dec 31, 2025Sale of Investments
133.83MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.31MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-16.19MUSDFY2025 · Dec 31, 2025Common Dividends Paid
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
-16.15MUSDFY2025 · Dec 31, 2025Shares Outstanding
100.70MSharesUpdated Aug 21, 2026Float Shares
46.79MSharesUpdated Aug 21, 2026% Held by Insiders
48.01%vs all stocks
% Held by Institutions
10.42%vs all stocks
Total Cash (MRQ)
143.90MUSD168.01M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.29USDUpdated Aug 21, 2026Total Debt (MRQ)
69.37MUSD80.99M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.96xvs Biotechnology peers
Current Ratio (MRQ)
1.37xvs Biotechnology peers
Book Value per Share (MRQ)
0.4878USDUpdated Aug 21, 2026Total Assets
324.72MUSDvs all stocks (USD)
Total Current Assets
236.25MUSDFY2025 · Dec 31, 2025Total Liabilities
248.82MUSDFY2025 · Dec 31, 2025Total Non-current Assets
88.48MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
103.07MUSDFY2025 · Dec 31, 2025Total Current Liabilities
145.75MUSDFY2025 · Dec 31, 2025Cash
45.91MUSDFY2025 · Dec 31, 2025Cash Equivalents
15.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
61.53MUSDFY2025 · Dec 31, 2025Other Short-term Investments
147.13MUSDFY2025 · Dec 31, 2025Accounts Receivable
14.40MUSDFY2025 · Dec 31, 2025Accounts Payable
17.28MUSDFY2025 · Dec 31, 2025Short-term Debt
11.79MUSDFY2025 · Dec 31, 2025Deferred Revenue
96.80MUSDFY2025 · Dec 31, 2025Other Current Liabilities
7.87MUSDFY2025 · Dec 31, 2025Long-term Debt
78.94MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
738.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.90MUSDFY2025 · Dec 31, 2025Retained Earnings
-334.13MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
75.90MUSDvs all stocks (USD)
52-Week Low
2.03EURUpdated Aug 21, 202652-Week High
4.84EURUpdated Aug 21, 202652-Week Change
17.21%vs all stocks
Beta
2.75xvs all stocks
50-Day MA
2.57EURUpdated Aug 21, 2026200-Day MA
3.24EURUpdated Aug 21, 2026Avg 10-Day Volume
117.78KSharesUpdated Aug 21, 2026Avg 30-Day Volume
114.72KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.5600USDUpdated Aug 21, 2026Other Income / Expense
-36.33MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.96×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.96Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: -1.02
Significant cash reserves alongside high leverageNotable
Cash (USD): 168,012,925.432Total Debt (USD): 80,989,636.845Debt-to-Equity: 1.96
Financial Health
Altman Z-Score -0.65: distress zoneCritical
Altman Z-Score: -0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jushri Technologies Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Lakala Payment Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Sichuan Dawn Precision Technology Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated